{
    "id": 4473,
    "name": "sarcomatoid renal cell carcinoma",
    "source": "DOID",
    "definition": null,
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:4473",
    "evidence": [
        
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT03024996",
            "title": "A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1201,
                    "therapyName": "Atezolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03866382",
            "title": "Cabozantinib in Combination With Nivolumab and Ipilimumab in Rare Genitourinary Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2067,
                    "therapyName": "Cabozantinib + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 2068,
                    "therapyName": "Cabozantinib + Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04267120",
            "title": "Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 4782,
                    "therapyName": "Lenvatinib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        }
    ]
}